Investor Presentation, page-52

shock horror! Different people with medical/scientific backgrounds using same scientific terminology to describe same trial. Yes very dodgy. Which terminologies are you confused about? I’d be happy to offer references to help.
remember it’s only in the last 6 or 9 months that the main trial results have been finally fully laid out for market so shouldn’t surprise anyone that people who know about trials and this cancer will come out to scrutinise it to see what looks right ....or where someone’s trying to hoodwink the market . fine if you think this isn’t the right forum for that, but as the data is everything and the company is reliant on perceived strength of trial to raise capital, personally I think it’s ok to comment here and offer verifiable facts.